Can Haemonetics cover its short-term obligations?

Its current ratio is 2.95 — current assets exceed current liabilities.

Where does Haemonetics's balance sheet data come from?

Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Haemonetics HAE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'26	FY'25	FY'24	FY'23
Cash and cash equivalents	$245.44M-20.0%	$306.76M+71.6%	$178.8M-37.1%	$284.47M+9.6%
Accounts receivable, net	$216.86M+7.0%	$202.66M-1.9%	$206.56M+15.3%	$179.14M+12.4%
Inventories	$306.37M-16.1%	$365.14M+15.1%	$317.2M+22.3%	$259.38M-11.5%
Raw materials	——	$128.57M-4.2%	$134.15M+16.6%	$115.02M+29.4%
Work in process	——	$14.96M-3.4%	$15.49M+23.2%	$12.57M-26.9%
Finished goods	——	$221.61M+32.3%	$167.56M+27.1%	$131.79M-29.5%
Prepaid expenses and other current assets	$66.21M+9.6%	$60.41M-8.9%	$66.34M+41.9%	$46.74M+5.9%
Contract assets	——	$11.6M—	——	——
Total current assets	$834.88M-10.7%	$934.98M+21.6%	$768.9M-0.1%	$769.72M+1.8%
Property and equipment, net	$305.76M+7.6%	$284.05M-8.8%	$311.36M+0.2%	$310.89M+20.3%
Accumulated depreciation	——	$553.14M-14.6%	$647.82M+2.3%	$633.33M+68.2%
Goodwill	$656.37M+8.6%	$604.27M+6.9%	$565.08M+21.2%	$466.23M-0.2%
Intangible assets, net	$447.66M-1.8%	$455.74M+12.2%	$406.12M+47.3%	$275.77M-11.1%
Deferred tax assets	$38.05M-39.2%	$62.58M-0.1%	$62.64M+73.1%	$36.2M+26.0%
Other non-current assets	$141.74M-13.6%	$164.11M+20.3%	$136.39M+27.5%	$106.98M+69.3%
Long-term investments	——	$61.6M—	——	——
Total assets	$2.4B-2.2%	$2.45B+11.6%	$2.2B+13.5%	$1.93B+4.0%
Accounts payable	$51.06M-23.8%	$67M-8.7%	$73.36M+14.7%	$63.93M+9.5%
Accrued expenses	$68.19M+14.8%	$59.42M-26.4%	$80.71M+25.2%	$64.48M+32.8%
Deferred revenue	——	——	——	——
Current portion of long-term debt	$5.02M-98.3%	$303.56M+2,868%	$10.23M-13.2%	$11.78M-94.5%
Contract liabilities	——	$43.3M+38.8%	$31.2M+3.3%	$30.2M+12.7%
Total current liabilities	$282.6M-51.1%	$578.11M+92.5%	$300.38M+19.3%	$251.82M-43.1%
Long-term debt	$1.22B+32.4%	$921.23M+15.5%	$797.56M+5.8%	$754.1M+34.8%
Other non-current liabilities	$59.39M-12.9%	$68.19M-9.1%	$75.04M+0.4%	$74.72M-6.5%
Common stock	$453K-6.0%	$482K-5.1%	$508K+0.8%	$504K-1.4%
Additional paid-in capital	$554.14M+5.9%	$523.26M-17.5%	$634.63M+6.7%	$594.71M+3.9%
Retained earnings	$279.34M-20.7%	$352.17M-2.3%	$360.46M+42.4%	$253.17M+25.1%
Accumulated other comprehensive income (loss)	-$37.61M+31.7%	-$55.08M-54.6%	-$35.63M-17.3%	-$30.38M-17.1%
Total stockholders' equity	$796.32M-3.0%	$820.84M-14.5%	$959.96M+17.4%	$818M+9.2%
Total liabilities and stockholders' equity	$2.4B-2.2%	$2.45B+11.6%	$2.2B+13.5%	$1.93B+4.0%
Allowance for Doubtful Accounts	——	$6.3M+10.6%	$5.7M+15.5%	$4.93M+99.3%
Allowance for Doubtful Accounts Receivable (Current)	——	$6.3M+10.6%	$5.7M+15.5%	$4.93M+99.3%
Finished goods	——	$221.61M+32.3%	$167.56M+27.1%	$131.79M-29.5%
Deferred Tax Assets and Other Non-Current Assets	$141.74M-13.6%	$164.11M+20.3%	$136.39M+27.5%	$106.98M+69.3%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	——	$762.87M-9.5%	$843.1M+25.3%	$672.72M—
Finite-Lived Intangible Assets, Net	——	——	——	——
Indefinite-Lived Intangible Assets	——	$9.19M-49.6%	$18.23M-10.9%	$20.47M—
Indefinite-Lived Intangible Assets, Gross	——	$9.19M-49.6%	$18.23M-10.9%	$20.47M—
Indefinite-Lived Research and Development Assets	——	$9.19M-49.6%	$18.23M-10.9%	$20.47M—
Indefinite-Lived Trademarks	——	$9.19M-49.6%	$18.23M-10.9%	$20.47M—
Deferred tax assets	$9.52M+22.0%	$7.8M+0.8%	$7.74M+47.7%	$5.24M+17.3%
Intangible assets — net	——	$446.55M+15.1%	$387.88M+51.9%	$255.3M—
Other intangible assets—net	$447.66M-1.8%	$455.74M+12.2%	$406.12M+47.3%	$275.77M-11.1%
Investments	——	$61.6M—	——	——
Other non-current assets	$141.74M-13.6%	$164.11M+20.3%	$136.39M+27.5%	$106.98M+69.3%
Property, plant and equipment at cost	——	$837.19M-12.7%	$959.18M+1.6%	$944.22M—
Software and Technology Licenses, Net	$141.74M-13.6%	$164.11M+20.3%	$136.39M+27.5%	$106.98M+69.3%
Accrued Manufacturing Costs	$68.19M+14.8%	$59.42M-26.4%	$80.71M+25.2%	$64.48M+32.8%
Compensation and benefits	$68.19M+14.8%	$59.42M-26.4%	$80.71M+25.2%	$64.48M+32.8%
Other accrued liabilities	$158.34M+6.9%	$148.13M+8.9%	$136.09M+21.9%	$111.63M-7.9%
Restructuring Reserve	——	$3.03M-74.4%	$11.79M+449%	$2.15M-23.4%
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Total debt	$1.27B-0.7%	$1.28B+46.9%	$873.88M+5.4%	$828.95M-0.9%
Common Stock Par Value Per Share	——	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	——	48.2M-5.1%	50.8M+0.7%	50.4M-1.3%
Additional paid-in capital	$554.14M+5.9%	$523.26M-17.5%	$634.63M+6.7%	$594.71M+3.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$453K-6.0%	$482K-5.1%	$508K+0.8%	$504K-1.4%
Cumulative Cost Basis	——	$837.19M-12.7%	$959.18M+1.6%	$944.22M—
Deferred Revenue Timing Percentage	——	——	——	——
Accounts Receivable, Allowance for Credit Loss	——	$6.3M+10.6%	$5.7M+15.5%	$4.93M+99.3%
Allowance for doubtful accounts	——	$6.3M+10.6%	$5.7M+15.5%	$4.93M+99.3%
Common stock, par value (in dollars per share)	——	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	——	$150M0.0%	$150M0.0%	$150M0.0%
Common stock, shares issued (in shares)	——	$48.22M-5.1%	$50.79M+0.7%	$50.45M-1.3%
Common Stock, Shares, Outstanding	——	$48.22M-5.1%	$50.79M+0.7%	$50.45M-1.3%
Consolidated interest coverage ratio	——	——	——	——
Consolidated total leverage ratio	——	——	——	——
Contract with Customer, Liability	——	$43.3M+38.8%	$31.2M+3.3%	$30.2M+12.7%
Debt instrument, percent of principal amount due in years 1-3	——	——	——	——
Debt instrument, percent of principal amount due in year 4	——	——	——	——
Debt instrument, percent of principal amount due in year 5	——	——	——	——
Deferred income taxes	$38.05M-39.2%	$62.58M-0.1%	$62.64M+73.1%	$36.2M+26.0%
Finite-Lived Intangible Assets, Accumulated Amortization	——	$316.31M-30.5%	$455.21M+9.1%	$417.42M+10.9%
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Intangible assets at fair value	——	——	——	——
Gross Carrying Amount	——	$762.87M-9.5%	$843.1M+25.3%	$672.72M—
Trademarks	——	$9.19M-49.6%	$18.23M-10.9%	$20.47M—
2028	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Thereafter	——	——	——	——
Long-Lived Assets	——	$284.05M—	——	——
Number of Interest Rate Swaps Remaining	——	——	——	——
Restructuring Reserve	——	$3.03M-74.4%	$11.79M+449%	$2.15M-23.4%
Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Haemonetics cover its short-term obligations?: Its current ratio is 2.95 — current assets exceed current liabilities.
Where does Haemonetics's balance sheet data come from?: Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.